Soft Tissue Sarcoma Competitive Landscape Analysis 2024: 361 Molecules in the Pipeline, Including 10 Drugs in the Late-stage Pipeline with Roche, BMS, Novartis, and Boehringer Ingelheim Leading Dublin, July 31, 2024 (GLOBE NEWSWIRE) -- The "Soft Tissue Sarcoma: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. This report provides a data-driven...

Soft Tissue Sarcoma Market to Propel by 2032, Predicts DelveInsight | Key Companies in the Market - Monopar, Jazz, Tracon, C4, Eli Lilly, Epizyme, Ipsen, GlaxoSmithKline, Salarius, Merck, Agenus, Mirati New York, USA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Soft Tissue Sarcoma Market to Propel by 2032, Predicts DelveInsight | Key Companies in the Market - Monopar, Jazz, Tracon, C4, Eli Lilly, Epizyme,...

Europe Soft Tissue Sarcoma Market Report 2023: Growing Focus on Personalized Medicine Presents Opportunities Dublin, May 31, 2023 (GLOBE NEWSWIRE) -- The "Europe Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type, By End...

The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030, growing at an annualized rate of 27.54% during the period 2021-2030, claims Roots Analysis London, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Soft Tissue Sarcoma Market: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report...